Agents for treating disorders involving modulation of ryanodine receptors

1. A compound represented by the structure of Formula (I):

wherein

R is COOH;

and pharmaceutically acceptable salts thereof.

2. The compound according to claim 1 , in the form of a salt with a pharmaceutically acceptable acid or base.

3. The compound according to claim 2 , wherein the salt is selected from the group consisting of sodium, potassium, magnesium, hemifumarate, hydrochloride and hydrobromide.

4. The compound according to claim 3 , wherein the salt is the sodium or the hemifumarate salt.

5. The compound according to claim 1 , which is selected from the group consisting of:

6. The compound according to claim 1 , which is represented by the structure of Formula (1):

or pharmaceutical y acceptable salts thereof.

7. The compound according to claim 6 , in the form of a salt with a pharmaceutically acceptable acid or base.

8. The compound according to claim 7 , wherein the salt is selected from the group consisting of sodium, potassium, magnesium, hemifumarate, hydrochloride and hydrobromide.

9. The compound according to claim 8 , wherein the salt is the sodium salt.

10. The compound according to claim 8 , wherein the salt is the hemifumarate salt.

11. A pharmaceutical composition comprising a compound according to claim 1 , in combination with one or more pharmaceutically acceptable excipients or carriers.

12. A method of treating a condition selected from the group consisting of cardiac disorders and diseases, muscle fatigue, musculoskeletal disorders and diseases; CNS disorders and diseases, cognitive dysfunction, neuromuscular disorders and diseases, bone disorders and diseases, cancer cachexia, malignant hyperthermia, diabetes, sudden cardiac death, and sudden infant death syndrome, or for improving cognitive function, the method comprising the step of administering to a subject in need thereof a therapeutically effective amount of a compound according to claim 1 or a pharmaceutical composition comprising such compound, to effectuate such treatment;

wherein the cardiac disorders and diseases are selected from the group consisting of irregular heartbeat disorders and diseases, exercise-induced irregular heartbeat disorders and diseases, heart failure, congestive heart failure, chronic heart failure, acute heart failure, systolic heart failure, diastolic heart failure, acute decompensated heart failure, cardiac ischemia/reperfusion (I/R) injury, chronic obstructive pulmonary disease, I/R injury following coronary angioplasty or following thrombolysis for the treatment of myocardial infarction (MI); and high blood pressure;

wherein the musculoskeletal disorders or diseases are selected from the group consisting of exercise-induced skeletal muscle fatigue, a congenital myopathy, muscular dystrophy, spinal muscular atrophy (SMA), spinal and bulbar muscular atrophy (SBMA), age-related muscle fatigue, sarcopcnia, central core disease, cancer cachexia, bladder disorders, and incontinence:

wherein the muscle fatigue is due to a skeletal muscle disease, disorder or condition;

wherein, the CNS disorders and diseases are selected from the group consisting of Alzheimer's Disease (AD), neuropathy, seizures, Parkinson's Disease (PD), and Huntington's Disease (HD); and the neuromuscular disorders and diseases are selected from the group consisting of spinocerebellar ataxia (SCA), and Amyotrophic lateral sclerosis (ALS, Lou Gehrig's disease);

wherein the cognitive dysfunction is stress-related or age-related, or wherein the cognitive function to be improved is short term memory, long term memory, attention or learning, or wherein the cognitive dysfunction is associated with a disease or disorder selected from the group consisting of Alzheimer's disease (AD), attention deficit hyperactivity disorder (ADHD), autism spectrum disorder (ASD), generalized anxiety disorder (GAD), obsessive compulsive disorder (OCD), Parkinson's Disease (PD), post-traumatic stress disorder (PTSD), Schizophrenia, Bipolar disorder, and major depression.

13. The method according to claim 12 , wherein the condition is associated with an abnormal function of a ryanodine receptor 1 (RyR1), a ryanodine receptor type (RyR2), a ryanodine receptor type 3 (RyR3), or a combination thereof.

14. The method according to claim 12 , wherein the compound is administered to a subject to treat cardiac disorders and diseases selected from the group consisting of irregular heartbeat disorders and diseases, exercise-induced irregular heartbeat disorders and diseases, heart failure, congestive heart failure, chronic heart failure, acute heart failure, systolic heart failure, diastolic heart failure, acute decompensated heart failure, cardiac ischemia/reperfusion (I/R) injury, chronic obstructive pulmonary disease, I/R injury following coronary angioplasty or following thrombolysis for the treatment of myocardial infarction (MI); and high blood pressure.

15. The method according to claim 12 , wherein the irregular heartbeat disorders and diseases are selected from the group consisting of atrial and ventricular arrhythmia, atrial and ventricular fibrillation, atrial and ventricular tachyarrhythmia, atrial and ventricular tachycardia, catecholaminergic polymorphic ventricular tachycardia (CPVT), and exercise-induced variants thereof.

16. The method according to claim 12 , wherein the compound is administered to a subject to treat muscle fatigue that is due to a skeletal muscle disease, disorder or condition.

17. The method according to claim 12 , wherein the compound is administered to a subject to treat a musculoskeletal disorder or disease selected from the group consisting of exercise-induced skeletal muscle fatigue, a congenital myopathy, muscular dystrophy, spinal muscular atrophy (SMA), Spinal and bulbar muscular atrophy (SBMA), age-related muscle fatigue, sarcopenia, central core disease, cancer cachexia, bladder disorders, and incontinence.

18. The method according to claim 12 , wherein the muscular dystrophy is selected from the group consisting of Duchenne Muscular Dystrophy (DMD), Becker's Muscular Dystrophy (BMD), Limb-Girdle Muscular Dystrophy (LGMD), facioscapulohumeral dystrophy, myotonic muscular dystrophy, congenital muscular dystrophy (CMD), distal muscular dystrophy, Emery-Dreifuss muscular dystrophy, and oculopharyngeal muscular dystrophy.

19. The method according to claim 12 , wherein the compound is administered to a subject to treat CNS disorders and diseases selected from the group consisting of Alzheimer's Disease (AD), neuropathy, seizures, Parkinson's Disease (PD), and Huntington's Disease (HD); and the neuromuscular disorders and diseases are selected from the group consisting of Spinocerebellar ataxia (SCA), and Amyotrophic lateral sclerosis (ALS, Lou Gehrig's disease).

20. The method according to claim 12 , wherein the compound is administered to a subject to treat cognitive dysfunction that is stress-related or age-related, or to improve cognitive function selected from short term memory, long term memory, attention and learning, or wherein compound is administered to a subject to treat cognitive dysfunction associated with a disease or disorder selected from the group consisting of Alzheimer's disease (AD), attention deficit hyperactivity disorder (ADHD), autism spectrum disorder (ASD), generalized anxiety disorder (GAD), obsessive compulsive disorder (OCD), Parkinson's Disease (PD), post-traumatic stress disorder (PTSD), Schizophrenia, Bipolar disorder, and major depression.

21. The method according to claim 12 , wherein the condition is cancer cachexia.

22. The method according to claim 12 , wherein the compound is used at a dose sufficient to restore or enhance binding of calstabin2 to RyR2.

23. The method according to claim 12 , wherein the compound is used at a dose sufficient to restore or enhance binding of calstabin1 to RyR1.

24. The method according to claim 12 , wherein the compound is used at a dose sufficient to decrease Ca 2+ leak through a RyR channel.

25. The method according to claim 12 , further comprising the use of an antisense oligonucleotide (AO) which is specific for a splicing sequence in an mRNA of interest, for enhancing exon skipping in said mRNA of interest.

26. A method for treating a subject that has Duchenne Muscular Dystrophy (DMD), comprising the step of administering to said subject a compound according to claim 1 , or a pharmaceutical composition comprising such compound, in combination with an antisense oligonucleotide (AO) which is specific for a splicing sequence of at least one exon of the DMD gene.

27. A process for the preparation of a compound according to claim 1 , comprising the step of reacting a compounds of the formula

with a compound of the formula

wherein R a is COOR 1 or CN; R 1 is a C 1 -C 4 alkyl, and L is a leaving group to afford a compound of the formula:

 and

converting the group R 3 to the group R so as to afford a compound of formula (I).

28. The method according to claim 21 , wherein the cancer cachexia is due to a cancer having hone metastases.

29. The method according to claim 26 , wherein the AO is specific for a splicing sequence of exon 23, 45, 44, 50, 51 52 and/or 53 of the DMD gene.